drugset / Trial / NCT05593614

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)

NCT05593614

Phase 2 Active not recruiting 276 enrolled AlgoTherapeutix
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this clinical trial is to compare the efficacy of twice daily applications of ATX01 (10% \& 15%) versus placebo during a 12-week treatment period in treating chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivor patients.

Timeline

Start
2023-02-28
Primary completion
2024-09
Completion
2024-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Amitriptyline Small molecule 10 % Topical
Subject Amitriptyline Small molecule 15 % Topical